Kassim Rahawi

Company: Sanofi

Job title: Global Medical Director, Amlitelimab

Seminars:

Efficacy & Safety of Amlitelimab (an Anti-OX40 Ligand Antibody) in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2b Trial (STREAM-AD) 9:00 am

Amlitelimab is a fully human, nondepleting anti-OX40 Ligand (OX40L) monoclonal antibody that blocks OX40L-OX40 interactions upstream of T cell expansion and inflammatory cytokine production STREAM-AD (NCT05131477), a randomized, double-blind, placebo-controlled Phase 2b trial, included a 24-wk treatment period (Part 1), a 28-wk maintenance/withdrawal period (Part 2), and a 16-wk safety follow-up All four doses of…Read more

day: Conference Day Two